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Abstract Background: Dual inhibition of the mitogen-activated protein kinase pathway with
BRAF/MEK inhibitor (BRAFi/MEKi) therapy is a standard treatment for BRAFV600-
mutant metastatic melanoma and has historically been associated with grade III pyrexia or
photosensitivity depending on the combination used. The objective of this study was to fully
describe adverse events from the COLUMBUS study evaluating the most recent BRAF/MEK
inhibitor combination encorafenibþbinimetinib.
Patients and methods: Patients with locally advanced, unresectable or metastatic BRAFV600-
mutant melanoma were randomised to receive encorafenib 450 mg once daily plus binimetinib
45 mg twice daily, encorafenib 300 mg once daily or vemurafenib 960 mg twice daily. Adverse
events that represent known effects of available BRAFi and/or MEKi were evaluated.
R e s u l t s : T h e s a f e t y p o p u l a t i o n i n c l u d e d a t o t a l o f 5 7 0 p a t i e n t s
(encorafenibþbinimetinib Z 192; encorafenib Z 192; vemurafenib Z 186). Median duration
of exposure was longer with encorafenibþbinimetinib (51 weeks) than with encorafenib (31
weeks) or vemurafenib (27 weeks). Common BRAFi/MEKi toxicities with encorafe-
nibþbinimetinib were generally manageable, reversible and infrequently associated with
discontinuation. Pyrexia was less frequent with encorafenibþbinimetinib (18%) and encorafe-
nib (16%) than with vemurafenib (30%) and occurred later in the course of therapy with en-
corafenibþbinimetinib (median time to first onset: 85 days versus 2.5 days and 19 days,
respectively). The incidence of photosensitivity was lower with encorafenibþbinimetinib
(5%) and encorafenib (4%) than with vemurafenib (30%). The incidence of serous retinopathy
was higher with encorafenibþbinimetinib (20%) than with encorafenib (2%) or vemurafenib
(2%), but no patients discontinued encorafenibþbinimetinib because of this event.
Conclusion: Encorafenibþbinimetinib is generally well tolerated and has a low discontinuation
rate in patients with BRAFV600-mutant melanoma, with a distinct safety profile as compared
with other anti-BRAF/MEK targeted therapies.
Trial registration: ClinicalTrials.gov (Identifier: NCT01909453) and with EudraCT (number
2013-001176-38).
ª 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Activating BRAFV600 mutations occur in ~50% of pa-
tients with melanoma [1]. These mutations drive consti-
tutive activation of the mitogen-activated protein kinase
(MAPK) pathway, resulting in the development and pro-
gression of melanoma [2]. Dual inhibition of the MAPK
pathway with combination BRAF/MEK inhibitor
(BRAFi/MEKi) therapy is a standard treatment for pa-
tients with BRAFV600-mutant metastatic melanoma
[3e6]. Compared with BRAFi monotherapy, BRAF/
MEKi combination therapy improves survival while
reducing BRAFi-associated toxicities resulting from par-
adoxical MAPK pathway activation [3e7]. BRAF/MEKi
therapies are associated with characteristic adverse events
(AEs), but each of the established combinations (dabra-
fenib plus trametinib and vemurafenib plus cobimetinib)
has a distinct safety profile with unique toxicities that
impact overall tolerability and may impact the ability to
deliver optimal treatment. For example, pyrexia has been
observed in 51e53% of patients treated with dabrafenib
plus trametinib and has included serious febrile reactions
and multiple episodes. It was the leading cause of dose
interruption (30e32% of patients) or reduction (13e14%
of patients) and discontinuation (2e3% of patients) [3,4].
Furthermore, photosensitivity has been commonly seen in
patients treated with vemurafenib plus cobimetinib,
occurring in 48% of patients, with 5% presenting with
grade 3 photosensitivity [8].
The combination of encorafenib plus binimetinib has
demonstrated clinical activity and tolerability in the
Phase 3 COLUMBUS study in patients with BRAF
V600emutated melanoma [9,10]. This combination is
distinct in that encorafenib is an adenosine triphosphate-
competitive BRAF inhibitor that suppresses the MAPK
pathway in tumour cells that express several mutated
forms of BRAF kinase (eg, V600E,V600D and V600K
mutations), with a dissociation half-life that is more than
10 times longer (>30 h) than either dabrafenib or
vemurafenib [11]. Preclinical studies suggest that this
property could allow for sustained target inhibition and
enhance antitumour activity while reducing paradoxical
activation of MAPK pathways in normal tissues [11,12].
Binimetinib is an orally available, non-ATP competitive,
allosteric inhibitor of MEK1 and MEK2 [13]. Results
from part 1 of the COLUMBUS study demonstrated
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encorafenib/binimetinib combination provides favour-
able efficacy and tolerability profile, as evidenced by the
achievement of higher median dose intensities and longer
median treatment exposure [10].
These findings highlight the importance of defining
the AE profiles of each combination to provide clini-
cians with information needed to optimise treatment for
individual patients. The objective of this report was to
describe the incidence, course and management of class-
based AEs of from the COLUMBUS study.
2. Materials and methods
2.1. Study design and patients
COLUMBUS is a two-part, phase III, randomised, open-
label study being conducted at 162 hospitals in 28
countries. A detailed description of the study design is
provided in the original publications [10]. Briefly, patients
with locally advanced or unresectable or metastatic mel-
anoma with a BRAFV600E or BRAFV600K mutation
and Eastern Cooperative Oncology Group performance
status of 0 or 1 who were untreated or who had pro-
gressed on or after prior first-line immunotherapy were
randomised 1:1:1 to receive encorafenib 450 mg once
daily plus binimetinib 45 mg twice daily, encorafenib
300 mg once daily or vemurafenib 960 mg twice daily
until disease progression (per central review), death, un-
acceptable toxic effects or withdrawal of consent.
Throughout the study, dose modifications were permitted
based on tolerability and AEs.
2.2. Safety evaluations
Safety assessments included AE monitoring, physical
examinations and cardiac and clinical laboratory assess-
ments. All patients in the encorafenib plus binimetinib
group and only patients on the encorafenib and vemur-
afenib arms who had retinal abnormalities at baseline had
routine ophthalmic testing at each regularly scheduled visit
during the treatment period. For patients on the encor-
afenibandvemurafenibarmswithout retinal abnormalities
at baseline, routine ophthalmic testing was performed at
cycle 4 day 1 and every 12 weeks thereafter. Cardiac im-
aging by a multigated acquisition scan or
echocardiogram to assess left ventricular dysfunction was
performed at screening; at day 1 of cycle 2, 3, 6 and 9 and
every 12 weeks thereafter. AE severity was graded ac-
cording to the National Cancer Institute Common Termi-
nology Criteria for Adverse Events, version 4.03.
Individual AEs describing clinically significant risks iden-
tified in the non-clinical and clinical programs, as well-
knownclass effectswithBRAFiandMEKiwereevaluated.
2.3. Statistical methods
All patients who received at least one dose of study drug
and had at least one postbaseline safety assessment were
included in the safety analysis set. AEs recorded on or
before May 19, 2016 were included in the current anal-
ysis. Exposure-adjusted incidence rate (EAIR; per 100
patient-months of exposure to study drug) was calcu-
lated for each AE as the number of patients experiencing
the AE divided by the total exposure time at risk for the
AE, with the duration of study drug exposure contrib-
uted by an individual patient being truncated at the time
of first onset of the AE. All safety assessments are
described descriptively.
3. Results
A total of 577 patients were randomised; 570 received
treatment and were included in the safety analysis set
(encorafenib plus binimetinib Z 192;
encorafenib Z 192; vemurafenib Z 186).
Baseline characteristics were generally similar across
treatment groups (Table 1). The median duration of
exposure to study treatment was longer in the encor-
afenib plus binimetinib group (51 weeks for both com-
ponents) than with encorafenib (31 weeks) or
vemurafenib (27 weeks).
Table 1
Baseline demographics and clinical characteristics.
Characteristic COMBO450
n Z 192
ENCO300
n Z 192
VEM
n Z 186
Mean (SD) age, y 56 (14) 55 (13) 55 (14)
Male sex, % 60 56 58
ECOG performance status 0,a % 71 72 73
LDHULN, % 29 24 27
BRAF mutation status
(V600E/V600K), %
89/11 89/10b 88/12
Tumour stage at study entry, %
IIIB/IIIC 5 3 6
IVM1a 14 15 13
IVM1b 18 20 16
IVM1c 64 62 65
Number of organs involved, %
1 24 29 24
2 30 27 31
3 45 44 46
Prior immunotherapy,c % 30 30 30
Ipilimumab 4 5 4
Prior antiePD-1 or antiePD-L1 1 1 0
Interferons/interleukins 27 26 27
COMBO450, encorafenib 450 mg once daily plus binimetinib 45 mg
twice daily; ECOG, Eastern Cooperative Oncology Group; ENCO300,
encorafenib 300 mg once daily; LDH, lactate dehydrogenase; PD-1,
programmed cell death 1; PD-L1, programmed death ligand 1;
ULN, upper limit of normal; VEM, vemurafenib 960 mg twice daily.
a All other patients had ECOG performance status of 1.
b Two observations were indeterminate.
c Includes adjuvant and metastatic settings.
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Table 2
AEs by incidence and exposure-adjusted incidence rates.a
Adverse event COMBO450
n Z 192
ENCO300
n Z 192
VEM
n Z 186
n (%) EAIRa n (%) EAIRa n (%) EAIRa
General disorders and administration site conditions
Fatigueb 83 (43) 5.5 80 (42) 6.8 86 (46) 9.1
Pyrexiac 35 (18) 1.7 30 (16) 1.9 55 (30) 5.1
Peripheral edemad 25 (13) 1.2 18 (9) 1.1 27 (15) 2.1
Erythemae 14 (7) 0.6 30 (16) 1.9 32 (17) 2.4
Gastrointestinal disorders
Nausea 79 (41) 5.0 74 (39) 5.7 63 (34) 5.6
Diarrhoea 70 (37) 4.4 26 (14) 1.5 63 (34) 5.9
Vomitingf 57 (30) 3.1 52 (27) 3.4 29 (16) 2.1
Abdominal paing 54 (28) 3.0 32 (17) 2.0 29 (16) 2.1
Constipation 42 (22) 2.1 27 (14) 1.6 12 (7) 0.8
Musculoskeletal and connective tissue disorders
Arthralgiah 49 (26) 2.6 85 (44) 8.4 85 (46) 10.4
Myopathyi 45 (23) 2.2 64 (33) 5.0 41 (22) 3.3
Pain in extremity 21 (11) 1.0 42 (22) 2.8 25 (13) 1.9
Back pain 18 (9) 0.8 29 (15) 1.8 11 (6) 0.8
Skin and subcutaneous tissue disorders
Hyperkeratosisj 44 (23) 2.3 110 (57) 14.6 92 (50) 12.1
Rashk 42 (22) 2.2 79 (41) 7.2 99 (53) 14.3
Dry skinl 31 (16) 1.5 72 (38) 6.2 49 (26) 4.2
Alopecial,m 27 (14) 1.3 108 (56) 12.8 70 (38) 7.1
Pruritusn 24 (13) 1.1 59 (31) 4.6 39 (2.1) 3.4
PPE syndrome 13 (7) 0.6 98 (51) 9.8 26 (14) 1.9
Photosensitivityo 9 (5) 0.4 8 (4) 0.5 56 (30) 5.2
Nervous system disorders
Headachep 42 (22) 2.0 54 (28) 3.9 37 (20) 3.0
Dizzinessq 29 (15) 1.4 12 (6) 0.7 8 (4) 0.6
Neuropathyr 23 (12) 1.1 42 (22) 2.8 25 (13) 1.9
Eye disorders
Visual impairments 39 (20) 2.1 11 (6) 0.6 8 (4) 0.5
Serous retinopathyt 38 (20) 1.9 4 (2) 0.2 3 (2) 0.2
Vascular disorders
Hemorrhageu 36 (19) 1.7 21 (11) 1.2 16 (9) 1.1
Hypertensionv 22 (12) 1.0 11 (6) 0.6 21 (11) 1.5
Cardiac disorders
Left ventricular dysfunctionw 15 (8) 0.7 4 (2) 0.2 1 (1) 0.1
Neoplasms benign, malignant and unspecified disorders (of the skin)
Skin papillomax 14 (7) 0.6 20 (10) 1.2 36 (19) 2.9
CuSCCy 5 (3) 0.2 15 (8) 0.9 32 (17) 2.5
Basal cell carcinoma 3 (2) 0.1 2 (1) 0.1 3 (2) 0.2
AE, adverse event; COMBO450, encorafenib 450 mg once daily plus binimetinib 45 mg twice daily; CuSCC, cutaneous squamous cell carcinoma;
EAIR, exposure-adjusted incidence rates; ENCO300, encorafenib 300 mg once daily; PPE, palmar-plantar erythrodysesthesia; VEM, vemurafenib
960 mg twice daily.
a AE per 100 patient-months of exposure to study drug.
b Includes fatigue, asthenia.
c Includes pyrexia, body temperature increased, hyperpyrexia, hyperthermia.
d Includes peripheral edema, local swelling, localised edema, edema, peripheral swelling.
e Includes erythema, generalised erythema, plantar erythema.
f Includes vomiting, retching.
g Includes abdominal pain, abdominal discomfort, upper abdominal pain, epigastric discomfort, gastrointestinal pain.
h Includes arthralgia, arthropathy, joint stiffness.
i Includes muscle spasms, muscular weakness, myalgia, myositis.
j Includes hyperkeratosis, hyperkeratosis follicularis et parafollicularis, keratosis pilaris, lichenoid keratosis, palmoplantar keratoderma,
parakeratosis, skin hyperplasia.
k Includes rash, exfoliative rash, erythematous rash, follicular rash, generalised rash, macular rash, maculopapular rash, papular rash, pruritic
rash, vesicular rash.
l Includes dry skin, asteatosis, xeroderma, xerosis.
m Includes alopecia, alopecia totalis, diffuse alopecia.
n Includes pruritus, generalised pruritus, genital pruritus.
o Includes photosensitivity reaction, solar dermatitis.
p Includes headache, head discomfort, migraine.
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3.1. Adverse events
The incidence and EAIR of AEs are summarised in Table
2. The incidence and EAIR of selected AEs are presented
in Figs. 1 and 2, respectively; discontinuation rates, dose
modification rates, and time to first onset are summarised
in Table 3. EAIRs were included to account for differ-
ences in the duration of exposure among the treatment
groups. As can be seen in Table 2, the EAIRs for the
encorafenib plus binimetinib group were generally lower
relative to the other treatment groups. Additional event
characteristics are detailed in the following section.
3.2. Pyrexia
Pyrexia was less frequent with encorafenib plus bini-
metinib (18%) and encorafenib (16%) than with
vemurafenib (30%), and events with encorafenib plus
binimetinib occurred later in the course of therapy
(median [range] time to first onset, 85 [2e545] days
versus 2.5 [1e560] days and 19 [2e619] days, respec-
tively). Pyrexia was mild (grade I) for most of the pa-
tients in the encorafenib plus binimetinib group who
experienced it (23/35; 66%). No patients in the encor-
afenib plus binimetinib group experienced grade IV
pyrexia, and a minority (10/192; 5%) experienced more
than one episode. Pyrexia led to discontinuation in only
one of 192 (<1%) patients receiving encorafenib plus
binimetinib, and pyrexia-related dose interruptions/ad-
justments were uncommon (8/192; 4%).
The six serious AEs of pyrexia that occurred with
encorafenib plus binimetinib were not associated with
hypotension, chills/rigors, dehydration, renal failure or
syncope and were usually associated with concurrent
contributory factors such as disease progression or un-
derlying infection.
3.3. Gastrointestinal AEs (nausea, diarrhoea and
vomiting)
The incidence of nausea was similar across treatment
groups (encorafenib plus binimetinib: 41%; encorafenib:
39% and vemurafenib: 34%). In the encorafenib plus
binimetinib treatment group, 24% of patients experi-
enced grade I nausea; 15% grade II and 2% grade III.
Diarrhoea was reported in more number of patients
who receive encorafenib plus binimetinib (36%) and
vemurafenib (34%) than those who receive encorafenib
(14%). In the encorafenib plus binimetinib group, 24%
of patients experienced grade I diarrhoea; 10% grade II;
2% grade III and 0.5% grade IV.
The incidence of vomiting was 30% with encorafenib
plus binimetinib, 27% with encorafenib and 16% with
vemurafenib. In the encorafenib plus binimetinib group,
18% of patients experienced grade I vomiting; 10%
grade II and 2% grade III.
In the encorafenib plus binimetinib group, nausea,
diarrhoea and vomiting occasionally led to dose modi-
fication (8%, 4% and 7%, respectively); diarrhoea led to
study discontinuation in 1% of patients. The median
time to first onset was 29 days for both nausea (range:
1e614 days) and diarrhoea (range: 1e534 days) and 57
days for vomiting (range: 1e607 days).
3.4. Arthralgia
The incidence of arthralgia was lower with encorafenib
plus binimetinib (26%) than with encorafenib (44%) or
vemurafenib (46%), with a median (range) time to first
onset with combination therapy of 85 (1e708) days. In
the encorafenib plus binimetinib group, severe
arthralgia was uncommon; the incidence of grade I,
grade II and grade III events was 19%, 6% and 1%,
respectively. A minority of patients in the encorafenib
plus binimetinib group (2%) required dose interruption
or adjustment, and no patient discontinued because of
arthralgia.
3.5. Hyperkeratosis
The incidence of hyperkeratosis was lower with encor-
afenib plus binimetinib (23%) than with encorafenib
(57%) or vemurafenib (49%), with a median (range) time
to first onset in the combination group of 77 (1e408)
q Includes dizziness, balance disorder, vertigo.
r Includes dysesthesia, hyperesthesia, hypoesthesia, neuralgia, neuropathy peripheral, paresthesia, peripheral motor neuropathy, peripheral
sensory neuropathy, polyneuropathy, sciatica, sensory disturbance, sensory loss.
s Includes visual impairment, blurred vision, reduced visual acuity.
t Includes retinal detachment, chorioretinitis, chorioretinopathy, cystoid macular edema, macular retinal pigment epithelium detachment,
retinal pigment epithelium detachment, macular detachment, macular edema, metamorphopsia, retinal disorder, retinal exudates, retinal edema,
retinal pigment epitheliopathy, retinopathy, subretinal fluid.
u Includes rectal haemorrhage, hematochezia, haematuria, cerebral haemorrhage, epistaxis, haemorrhoidal haemorrhage, menorrhagia,
metrorrhagia, retinal haemorrhage, conjunctival haemorrhage, gastric ulcer haemorrhage, gastrointestinal haemorrhage, haematospermia,
haemorrhagic cyst, intracranial tumour haemorrhage, polymenorrhea, subdural haematoma, uterine haemorrhage, haemorrhagic diarrhoea,
haemoptysis, mucosal haemorrhage, occult blood, postprocedural haemorrhage, postmenopausal haemorrhage, pulmonary alveolar haemor-
rhage, tumour haemorrhage, vaginal haemorrhage, wound haemorrhage.
v Includes hypertension, essential hypertension, hypertensive crisis.
w Includes ejection fraction decreased, cardiac failure, left ventricular dysfunction and ejection fraction abnormal.
x Includes skin papilloma, papilloma, blepharal papilloma, oral papilloma.
y Includes keratoacanthoma, squamous cell carcinoma, lip squamous cell carcinoma, squamous cell carcinoma of skin.
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days. With encorafenib plus binimetinib, severe hyper-
keratosis was uncommon; the incidence of grade I, grade
II and grade III events was 17%, 5% and 1%, respec-
tively. A minority of patients in the encorafenib plus
binimetinib group (2%) required dose interruption or
adjustment, and no patient discontinued because of
hyperkeratosis.
3.6. Photosensitivity
The incidence of photosensitivity was lower with
encorafenib plus binimetinib (5%) and encorafenib (4%)
than with vemurafenib (30%) despite advice on mini-
mizing sun exposure [14], with a median (range) time to
first onset in the combination group of 84 (1e677) days.
With encorafenib plus binimetinib, all events were of
grade I or II, except for one grade III event. Only 1
patient (1%) in the combination group required dose
Fig. 1. Selected AEs occurring in patients (all grades) in any study group. AESI, adverse event of special interest; COMBO450, encor-
afenib 450 mg once daily plus binimetinib 45 mg twice daily; ENCO300, encorafenib 300 mg once daily; VEM, vemurafenib 960 mg twice
daily.
Fig. 2. Selected AEs by exposure-adjusted incidence rate. AESI, adverse event of special interest; COMBO450, encorafenib 450 mg once
daily plus binimetinib 45 mg twice daily; EAIR, exposure-adjusted incidence rates; ENCO300, encorafenib 300 mg once daily; VEM,
vemurafenib 960 mg twice daily. *EAIR per 100 patient-monthsZ(n*100)/(total exposure time [in months]).
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interruption or adjustment, and no patient discontinued
because of photosensitivity.
3.7. Serous retinopathy
The incidence of serous retinopathy was higher with
encorafenib plus binimetinib (20%) than with encor-
afenib (2%) or vemurafenib (2%), with a median (range)
time to first onset in the combination group of 38
(1e532) days. With encorafenib plus binimetinib, severe
serous retinopathy was uncommon; the incidence of
grade I (asymptomatic), grade II and grade III events
was 12%, 5% and 3%, respectively. Six percent of pa-
tients with encorafenib plus binimetinib required dose
interruption or adjustment, and no patient discontinued
because of serous retinopathy. Clinical review of serous
retinopathy events indicated that these events were
generally reversible, with 31/38 (82%) of events reported
as ‘recovered’ and 1/38 (3%) as ‘recovering’.
3.8. Left ventricular dysfunction
The incidence of left ventricular dysfunction (LVD) was
higher with encorafenib plus binimetinib (8%) than with
encorafenib (2%) or vemurafenib (1%), with a median
(range) time to first onset in the combination group of
109 (1e648) days. With encorafenib plus binimetinib,
severe LVD was uncommon; the incidence of grade I,
grade II and grade III events was 2%, 4% and 2%,
respectively. Six percent of patients receiving encor-
afenib plus binimetinib required dose interruption or
adjustment, and no patient discontinued because of
LVD. Clinical review of LVD events indicated that these
events were generally reversible upon dose reduction or
discontinuation, with 14/15 (93%) events reported as
‘recovered’ and one as ‘resolved with sequelae’.
4. Discussion
The results of the current analysis of safety data from
the COLUMBUS study suggest that common BRAFi/
MEKi AEs of interest evaluated in this article with
encorafenib plus binimetinib were generally manage-
able, reversible and infrequently associated with treat-
ment discontinuation. No serious unexpected AEs were
observed. Since the median duration of exposure was
nearly twice as long as in the encorafenib plus binime-
tinib group (51 weeks) compared with the vemurafenib
group (27 weeks) or the encorafenib group (31 weeks),
the EAIRs provide additional context when comparing
the incidence of AEs by accounting for how long a pa-
tient was exposed to the study treatment before experi-
encing an AE, if at all.
Despite the observed incidence rates being similar
across treatment groups, the EAIRs for several AEs
were lower for the encorafenib plus binimetinib group
relative to the other treatment groups, providing
compelling data in support of the tolerability of the
combination.
Although pyrexia has emerged as a common, often
recurrent, treatment-limiting effect associated with
dabrafenib plus trametinib therapy [3,4,15e17], it
occurred in 18% of patients treated with encorafenib
plus binimetinib in the COLUMBUS study versus 16%
of patients treated with encorafenib and 30% of patients
treated with vemurafenib. In previously reported phase
3 melanoma study, pyrexia related to vemurafenib was
reported in 21% of patients [18]. Furthermore, pyrexia
with encorafenib plus binimetinib in the current analysis
was typically limited to a single episode (only 10/192
[5%] experienced more than one episode) and rarely led
to dose interruption or adjustment (4%) or discontinu-
ation (<1%). Pyrexia associated with encorafenib plus
binimetinib therapy in the COLUMBUS study occurred
later during the course of treatment (median time to first
onset, 85 days [12.1 weeks] versus 4.3 weeks with dab-
rafenib plus trametinib therapy) [4], and serious pyrexia
events in the COLUMBUS study lacked association
with hypotension, chills/rigors, dehydration, renal
failure or syncope [19] (24% of patients treated with
dabrafenib plus trametinib in phase I/II studies experi-
enced concomitant chills, night sweats, influenza-like
illness, hypotension, cytokine-release syndrome and/or
systemic inflammatory response syndrome without a
documented increase in body temperature) [17]. Most
grade III pyrexia events were managed with treatment
interruption; antibiotics, antipyretics and steroids were
occasionally administered (n Z 4, 5 and 1, respectively)
[19]. In dabrafenib plus trametinib trials, pyrexia was
the most common reason for dose interruption (30e32%
Table 3
Characteristics of selected AEs in the combination encorafenib plus
binimetinib treatment group, by time to first onset.
AEs Median time
to first onset,
days (range)
Discontinuation,
%
Dose
modification,a
%
Nausea 29 (1e614) 0 8
Diarrhoea 29 (1e534) 1 4
Serous retinopathy 38 (1e532) 0 6
Vomiting 57 (1e607) 0 7
Hyperkeratosis 77 (1e408) 0 2
Photosensitivity 84 (1e677) 0 1
Pyrexia 85 (2e545) <1 4
Arthralgia 85 (1e708) 0 2
Left ventricular
dysfunction
109 (1e648) 0 6
AE, adverse event.
Median times to first onset are calculated only for those experiencing
the event. Discontinuation and dose modification percentages are
calculated using the number of patients in the combination encorafenib
plus binimetinib treatment group with the safety population as the
denominator (n Z 192).
a Dose modifications include dose interruptions and dose
adjustments.
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of patients), reduction (13e14% of patients) and
discontinuation (2e3% of patients, [3,4].
The incidence of photosensitivity with encorafenib
plus binimetinib (5%) was lower than that reported with
vemurafenib plus cobimetinib (28e48%) [5,6,8]. It was
typically mild (predominantly grade I or II) and rarely
interfered with the course of therapy (1 patient required
dose interruption, and no patient discontinued therapy).
Unlike photosensitivity associated with vemurafenib
plus cobimetinib, which is frequently recurrent and
long lasting [8], most patients who experienced photo-
sensitivity with encorafenib plus binimetinib experienced
a single event. The improvement in photosensitivity AEs
seen in patients treated with encorafenib plus binimeti-
nib may be due to the ultraviolet A-absorbing nature of
vemurafenib which is distinct relative to encorafenib
[14]. The pharmacokinetic profile of encorafenib in-
dicates prolonged binding to the target molecule,
thereby providing greater BRAF inhibition and
increased potency and specificity, which may also
contribute to the observed differences. These factors
may result in better tolerability, including reduced
occurrence of photosensitivity [20].
Serous retinopathy was mainly asymptomatic or of
low severity and reversible. Detection was predomi-
nantly through regular, specialised eye examination,
which, unlike prior similar trials, was protocol
mandated for all patients in the encorafenib plus bini-
metinib group. Our findings are consistent with previ-
ously published reports of MEKi-associated
retinopathy, in which symptoms are often mild and
transient, and retinal changes are typically reversible
[21e24]. Most patients who develop serous retinopathy
do not require pharmacologic intervention; however,
topical non-steroidal anti-inflammatory or carbonic
anhydrase inhibitors may be useful agents for select
patients seeking symptomatic relief [22]. Observed
MEKi-related toxic effects, including serous retinop-
athy, were largely in line with other BRAFi/MEKi
combination actively monitored trials [10].
LVD was uncommon among patients who received
encorafenib plus binimetinib therapy (8%) and was
typically of mild or moderate severity (grade I, 2%;
grade II, 4%; grade III, 2%). In this group, LVD was
typically managed by dose interruption and/or reduction
and was generally reversible without treatment discon-
tinuation. In clinical studies, approximately, 4e8% of
patients experienced decreased ejection fraction with
dabrafenib plus trametinib therapy, leading to discon-
tinuation in 1%e3% of patients [3,16]. This has been
primarily attributed to the trametinib component [25].
Gastrointestinal events such as nausea, diarrhoea,
vomiting, abdominal pain and constipation can occur
when treated with with encorafenib plus binimetinib.
Most events were of grade I or II. The average time to
nausea or diarrhoea was within the first month, and
vomiting was within the first two months of starting
treatment. Among patients who received encorafenib
plus binimetinib, nausea and vomiting were the most
common adverse reactions leading to dose in-
terruptions. Additional guidance on dose modifications
due to specific AEs associated with encorafenib or
binimetinib can be found in approved product labeling.
The differences in AEs discussed previously may be
related to the differences in the pharmacokinetic profiles
of these therapies. For example, encorafenib demon-
strated pharmacokinetic differences compared with
other BRAF inhibitors as reported in a phase I study in
metastatic BRAF-mutant melanomas. In a biochemical
assay, encorafenib inhibited BRAFV600E kinase activity
at similar concentrations as dabrafenib and vemur-
afenib; but with a considerably longer dissociation half-
life. In BRAFV600-mutant cell lines, encorafenib was
more potent at inhibiting proliferation relative to dab-
rafenib and vemurafenib. Single-dose pharmacokinetic/
pharmacodynamic studies in human melanoma xeno-
graft models (BRAFV600E) showed that encorafenib
resulted in strong and sustained decreases in pERK even
at low doses, consistent with a prolonged dissociation
half-life [11].
This detailed analysis of AEs in the COLUMBUS
study suggests that encorafenib plus binimetinib is
generally well tolerated and has a low discontinuation
rate in patients with BRAFV600-mutant melanoma,
with a distinct safety profile.
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